InsiderTrades.com logo
Corrine Savill net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Corrine Savill Biography and Net Worth

Chief Business Officer of Cullinan Therapeutics

Corinne is highly accomplished in pharmaceutical research and development, oncology and international business development. Prior to joining Cullinan Therapeutics, Corinne served as Global Head, Business Development and Licensing for Novartis Pharma. In this role, Corinne oversaw the execution and management of over 20 major transactions across multiple therapeutic areas including in-licensing, option and equity deals, spin-outs, and divestments. Corinne started her career as a researcher at AstraZeneca and Imutran, a UK-based biotech company, where she was Research Director. Novartis acquired Imutran in 1996 and Corinne was promoted to CEO of Imutran. Since 2001, Corinne continued to hold increasingly senior leadership positions within Novartis. She was the European Head of the Transplant and Immunology Business, the Global Head Search and Evaluation for Business Development and prior to her last role the Global Head of Pricing and Market Access where she was responsible for the price and access strategies for the entire Novartis portfolio.

Corinne received a B.S. in Biochemistry from the University of Manchester (UK) and conducted her postgraduate research at University College and Middlesex School of Medicine (Ph.D.) and the Charing Cross Sunley Research Centre in London.

What is Corrine Savill's net worth?

The estimated net worth of Corrine Savill is at least $1.76 million as of February 1st, 2024. Dr. Savill owns 165,990 shares of Cullinan Therapeutics stock worth more than $1,756,174 as of December 4th. This net worth approximation does not reflect any other assets that Dr. Savill may own. Learn More about Corrine Savill's net worth.

How do I contact Corrine Savill?

The corporate mailing address for Dr. Savill and other Cullinan Therapeutics executives is , , . Cullinan Therapeutics can also be reached via phone at 617-410-4650 and via email at [email protected]. Learn More on Corrine Savill's contact information.

Has Corrine Savill been buying or selling shares of Cullinan Therapeutics?

Corrine Savill has not been actively trading shares of Cullinan Therapeutics within the last three months. Most recently, Corrine Savill sold 40,000 shares of the business's stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $16.18, for a transaction totalling $647,200.00. Following the completion of the sale, the insider now directly owns 165,990 shares of the company's stock, valued at $2,685,718.20. Learn More on Corrine Savill's trading history.

Who are Cullinan Therapeutics' active insiders?

Cullinan Therapeutics' insider roster includes Nadim Ahmed (Pres), Nadim Ahmed (President and Chief Executive Officer), Ansbert Gadicke (Director), Jeffrey Jones (Chief Medical Officer), Jennifer Michaelson (Insider), Corrine Savill (Chief Business Officer), Jeffrey Trigilio (CFO), and Leigh Zawel (Insider). Learn More on Cullinan Therapeutics' active insiders.

Are insiders buying or selling shares of Cullinan Therapeutics?

During the last twelve months, Cullinan Therapeutics insiders bought shares 8 times. They purchased a total of 1,874,057 shares worth more than $13,325,286.34. During the last twelve months, insiders at the sold shares 7 times. They sold a total of 42,006 shares worth more than $444,804.13. The most recent insider tranaction occured on November, 24th when insider Jennifer Michaelson sold 4,000 shares worth more than $49,200.00. Insiders at Cullinan Therapeutics own 7.2% of the company. Learn More about insider trades at Cullinan Therapeutics.

Information on this page was last updated on 11/24/2025.

Corrine Savill Insider Trading History at Cullinan Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2024Sell40,000$16.18$647,200.00165,990View SEC Filing Icon  
1/29/2024Sell40,000$14.09$563,600.00165,990View SEC Filing Icon  
1/22/2024Sell18,684$12.14$226,823.76165,990View SEC Filing Icon  
7/18/2022Sell5,042$15.06$75,932.52164,573View SEC Filing Icon  
7/11/2022Sell40,000$13.33$533,200.00169,615View SEC Filing Icon  
See Full Table

Corrine Savill Buying and Selling Activity at Cullinan Therapeutics

This chart shows Corrine Savill's buying and selling at Cullinan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Cullinan Therapeutics Company Overview

Cullinan Therapeutics logo
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $10.58
Low: $10.08
High: $10.79

50 Day Range

MA: $8.26
Low: $5.75
High: $12.93

2 Week Range

Now: $10.58
Low: $5.68
High: $13.60

Volume

877,985 shs

Average Volume

1,211,674 shs

Market Capitalization

$625.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A